These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

220 related items for PubMed ID: 9753056

  • 21. Predominantly BCR-ABL negative myeloid precursors in interferon-alpha treated chronic myelogenous leukemia: a follow-up study of peripheral blood colony-forming cells with fluorescence in situ hybridization.
    Sick C, Schultheis B, Pasternak G, Kottke I, Hörner S, Heissig B, Hehlmann R.
    Ann Hematol; 2001 Jan; 80(1):9-16. PubMed ID: 11233781
    [Abstract] [Full Text] [Related]

  • 22. Monitoring the efficiency of interferon-alpha therapy in chronic myelogenous leukemia (CML) patients by competitive polymerase chain reaction.
    Hochhaus A, Lin F, Reiter A, Skladny H, Hehlmann R, Goldman JM, Cross NC.
    Leukemia; 1997 Apr; 11 Suppl 3():541-4. PubMed ID: 9209451
    [Abstract] [Full Text] [Related]

  • 23. Minimal residual disease in chronic myeloid leukaemia.
    Cross NC.
    Hematol Cell Ther; 1998 Oct; 40(5):224-8. PubMed ID: 9844816
    [Abstract] [Full Text] [Related]

  • 24.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 25. BCR/ABL mRNA and the P210(BCR/ABL) protein are downmodulated by interferon-alpha in chronic myeloid leukemia patients.
    Pane F, Mostarda I, Selleri C, Salzano R, Raiola AM, Luciano L, Saglio G, Rotoli B, Salvatore F.
    Blood; 1999 Oct 01; 94(7):2200-7. PubMed ID: 10498589
    [Abstract] [Full Text] [Related]

  • 26.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 27. Use of quantitative polymerase chain reaction to monitor residual disease in chronic myelogenous leukemia during treatment with interferon.
    Lion T, Gaiger A, Henn T, Hörth E, Haas OA, Geissler K, Gadner H.
    Leukemia; 1995 Aug 01; 9(8):1353-60. PubMed ID: 7643624
    [Abstract] [Full Text] [Related]

  • 28.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 29.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 30.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 31. Evidence for specific immune response against P210 BCR-ABL in long-term remission CML patients treated with interferon.
    Oka T, Sastry KJ, Nehete P, Schapiro SJ, Guo JQ, Talpaz M, Arlinghaus RB.
    Leukemia; 1998 Feb 01; 12(2):155-63. PubMed ID: 9519777
    [Abstract] [Full Text] [Related]

  • 32. Does BCR-ABL genomic rearrangement persist in CML patients in complete remission after interferon alpha therapy?
    Brizard F, Chomel JC, Veinstein A, Rivet J, Giraud C, Kitzis A, Guilhot F, Brizard A.
    Leukemia; 1998 Jul 01; 12(7):1076-80. PubMed ID: 9665193
    [Abstract] [Full Text] [Related]

  • 33. Serial monitoring of BCR-ABL by peripheral blood real-time polymerase chain reaction predicts the marrow cytogenetic response to imatinib mesylate in chronic myeloid leukaemia.
    Wang L, Pearson K, Pillitteri L, Ferguson JE, Clark RE.
    Br J Haematol; 2002 Sep 01; 118(3):771-7. PubMed ID: 12181044
    [Abstract] [Full Text] [Related]

  • 34. Accurate and rapid analysis of residual disease in patients with CML using specific fluorescent hybridization probes for real time quantitative RT-PCR.
    Emig M, Saussele S, Wittor H, Weisser A, Reiter A, Willer A, Berger U, Hehlmann R, Cross NC, Hochhaus A.
    Leukemia; 1999 Nov 01; 13(11):1825-32. PubMed ID: 10557058
    [Abstract] [Full Text] [Related]

  • 35. [Monitoring bcr-abl mRNA levels by real-time quantitative RT-PCR in chronic myeloid leukemia patients after hematopoietic stem cell transplantation].
    Qin YZ, Li JL, Zhu HH, Ruan GR, Li LD, Zhang Y, Xu LP, Liu DH, Liu YR, Huang XJ, Chen SS, Lu DP.
    Zhonghua Xue Ye Xue Za Zhi; 2006 Aug 01; 27(8):511-4. PubMed ID: 17172121
    [Abstract] [Full Text] [Related]

  • 36. Persistence of myeloid progenitor cells expressing BCR-ABL mRNA after allogeneic bone marrow transplantation for chronic myelogenous leukemia.
    Pichert G, Alyea EP, Soiffer RJ, Roy DC, Ritz J.
    Blood; 1994 Oct 01; 84(7):2109-14. PubMed ID: 7919323
    [Abstract] [Full Text] [Related]

  • 37. A comparison of the sensitivity of blood and bone marrow for the detection of minimal residual disease in chronic myeloid leukaemia.
    Lin F, Goldman JM, Cross NC.
    Br J Haematol; 1994 Mar 01; 86(3):683-5. PubMed ID: 8043457
    [Abstract] [Full Text] [Related]

  • 38. Bcr-abl-positive and -negative clonogenic cells in CML patients undergoing long-term interferon treatment.
    Wandl UB, Bützler R, Niederle N, Kloke O, Mengelkoch B, Becher R, Seeber S, Opalka B.
    Leukemia; 1994 May 01; 8(5):776-9. PubMed ID: 7514245
    [Abstract] [Full Text] [Related]

  • 39. [Monitoring of minimal residual disease in patients with chronic myeloleukemia: clinical value of real-time polymerase chain reaction].
    Chelysheva EIu, Turkina AG, Misiurin AV, Aksenova EV, Domracheva EV, Zakharova AV, Khoroshko ND.
    Ter Arkh; 2007 May 01; 79(4):49-53. PubMed ID: 17564019
    [Abstract] [Full Text] [Related]

  • 40. Evaluation of minimal residual disease in patients with chronic myeloid leukaemia on IFN-alpha 2b therapy using conventional cytogenetics and fluorescence in situ hybridization.
    Talwar R, Choudhry VP, Jobanputra V, Kucheria K.
    Natl Med J India; 2002 May 01; 15(4):195-8. PubMed ID: 12296472
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 11.